PCM 075

Drug Profile

PCM 075

Alternative Names: NMS-1286937; NMS-P937; PCM075

Latest Information Update: 11 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nerviano Medical Sciences
  • Developer Nerviano Medical Sciences; TrovaGene
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Polo-like kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Acute myeloid leukaemia; Non-Hodgkin's lymphoma

Most Recent Events

  • 10 Oct 2017 Trovagene plans a phase Ib/II trial for Acute myeloid leukaemia (Combination therapy, Second-line therapy or greater) in USA in October 2017 (PO) (NCT03303339)
  • 09 Oct 2017 PCM 075 receives Orphan Drug status for Acute myeloid leukaemia in USA
  • 21 Aug 2017 Pharmacodynamics data from a preclinical study in Non-Hodgkin's lymphoma released by Trovagene
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top